Vertex Pharmaceuticals Total Debt vs. Debt To Equity
| VRTX34 Stock | BRL 619.20 14.62 2.42% |
For Vertex Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vertex Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vertex Pharmaceuticals Incorporated utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vertex Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vertex Pharmaceuticals Incorporated over time as well as its relative position and ranking within its peers.
Vertex |
Vertex Pharmaceuticals Debt To Equity vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vertex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vertex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Vertex Pharmaceuticals Incorporated is rated fifth in total debt category among its peers. It is rated third in debt to equity category among its peers . The ratio of Total Debt to Debt To Equity for Vertex Pharmaceuticals Incorporated is about 5,255,670,103 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vertex Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vertex Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Vertex Total Debt vs. Competition
Vertex Pharmaceuticals Incorporated is rated fifth in total debt category among its peers. Total debt of Biotechnology industry is at this time estimated at about 12.02 Billion. Vertex Pharmaceuticals holds roughly 509.8 Million in total debt claiming about 4% of stocks in Biotechnology industry.
Vertex Debt To Equity vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Vertex Pharmaceuticals |
| = | 509.8 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Vertex Pharmaceuticals |
| = | 0.1 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Vertex Debt To Equity Comparison
Vertex Pharmaceuticals is rated second in debt to equity category among its peers.
Vertex Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vertex Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vertex Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Vertex Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Vertex Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 3400 people.
Vertex Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vertex Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vertex Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vertex Pharmaceuticals' important profitability drivers and their relationship over time.
Use Vertex Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vertex Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vertex Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Vertex Pharmaceuticals Pair Trading
Vertex Pharmaceuticals Incorporated Pair Trading Analysis
The ability to find closely correlated positions to Vertex Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vertex Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vertex Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vertex Pharmaceuticals Incorporated to buy it.
The correlation of Vertex Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vertex Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vertex Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vertex Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vertex Pharmaceuticals position
In addition to having Vertex Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 99 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Vertex Stock
To fully project Vertex Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Vertex Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Vertex Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.